Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday.

According to Zacks, “Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom. “

Other equities research analysts also recently issued reports about the company. SunTrust Banks, Inc. started coverage on Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a “buy” rating and a $26.00 price target for the company. Stifel Nicolaus started coverage on Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a “buy” rating and a $22.00 price target for the company. Jefferies Group LLC restated a “buy” rating and issued a $26.00 price target on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. Finally, Wedbush started coverage on Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued an “outperform” rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $22.60.

Verona Pharma PLC American Depositary Share (VRNA) opened at 12.2702 on Thursday. The stock’s market cap is $78.77 million. Verona Pharma PLC American Depositary Share has a 1-year low of $11.03 and a 1-year high of $17.50. The firm’s 50-day moving average price is $14.21 and its 200 day moving average price is $13.74.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.09. Equities research analysts expect that Verona Pharma PLC American Depositary Share will post ($2.23) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Verona Pharma PLC American Depositary Share (VRNA) Rating Increased to Hold at Zacks Investment Research” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/08/17/verona-pharma-plc-american-depositary-share-vrna-rating-increased-to-hold-at-zacks-investment-research.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tekla Capital Management LLC purchased a new position in Verona Pharma PLC American Depositary Share during the second quarter worth about $3,211,000. FIL Ltd purchased a new position in Verona Pharma PLC American Depositary Share during the second quarter worth about $873,000. Finally, Vivo Capital LLC purchased a new position in Verona Pharma PLC American Depositary Share during the second quarter worth about $8,208,000. Institutional investors and hedge funds own 10.46% of the company’s stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.